← Back to Search

Multivitamin/Mineral Supplement

Redoxon VI for Vitamin D Deficiency

N/A
Waitlist Available
Led By Adrian F Gombart, PhD
Research Sponsored by Oregon State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks

Summary

This trial tests a daily supplement containing vitamins C, D, and zinc in adults aged 60 to 75. The goal is to see if the supplement can improve the ability of white blood cells to kill bacteria. Researchers believe that these nutrients will help older adults' immune systems work better by making their white blood cells more effective at fighting infections.

Eligible Conditions
  • Vitamin D Deficiency

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
S. aureus clearance from whole blood
Secondary study objectives
Determine phagocytic activity of neutrophils by measuring uptake of fluorescently labeled Escherichia coli using flow cytometry
Number of neutrophils, monocytes and lymphocytes
Serum levels of inflammatory cytokines
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Redoxon VIExperimental Treatment1 Intervention
2 film coated tablets Redoxon VI oral intake daily for 12 weeks
Group II: PlaceboPlacebo Group1 Intervention
2 film coated tablets placebo oral intake daily for 12 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Redoxon VI
2016
N/A
~50

Find a Location

Who is running the clinical trial?

Oregon State UniversityLead Sponsor
50 Previous Clinical Trials
8,392 Total Patients Enrolled
Adrian F Gombart, PhDPrincipal InvestigatorPrincipal Investigator
~5 spots leftby Dec 2025